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Abstract
Background: Stem cell antigen-1 (Sca-1 or Ly6A) is a glycosyl phostidylinositol (GPI)-anchored cell surface protein associated
with both stem and progenitor activity, as well as tumor initiating-potential. However, at present the functional role for Sca-
1 is poorly defined.
Methodology/Principal Findings: To investigate the role of Sca-1 in mammary tumorigenesis, we used a mammary cell line
derived from a MMTV-Wnt1 mouse mammary tumor that expresses high levels of endogenous Sca-1. Using shRNA
knockdown, we demonstrate that Sca-1 expression controls cell proliferation during early tumor progression in mice.
Functional limiting dilution transplantations into recipient mice demonstrate that repression of Sca-1 increases the
population of tumor propagating cells. In scratch monolayer assays, Sca-1 enhances cell migration. In addition, knockdown
of Sca-1 was shown to affect cell adhesion to a number of different extracellular matrix components. Microarray analysis
indicates that repression of Sca-1 leads to changes in expression of genes involved in proliferation, cell migration, immune
response and cell organization.
Conclusions/Significance: Sca-1 exerts marked effects on cellular activity and tumorgenicity both in vitro and in vivo.A
better understanding of Sca-1 function may provide insight into the broader role of GPI-anchored cell surface proteins in
cancer.
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Introduction
Stem cell antigen-1 (Sca-1 or Ly6A) is a member of the Ly6
family of glycosyl phostidylinositol (GPI)-anchored cell surface
proteins. Sca-1 has been long associated with murine stem/
progenitor cells [1] and is localized to lipid rafts where it regulates
signaling complexes [2]. Functional studies using Sca-1-null mice
have revealed several phenotypes. Interferon-stimulated hemato-
poietic stem cells (HSCs) upregulate Sca-1 in a Stat1-dependent
manner. Additionally, minor defects in lineage skewing were
observed in the hematopoietic system of Sca-1-null mice.
Osteoporosis and reduced muscle size were observed in aging
Sca-1-null mice. Moreover, Sca-1 is necessary for matrix
metalloproteinase (MMP) activity during muscle repair.
Initial studies in the mammary gland showed that Sca-1
+ cells
have increased regenerative capacity compared to Sca-1
2 cells [3].
Subsequent studies involving purified mammary stem cells with
repopulating activity using CD24 in combination with CD29 (b1
integrin) or CD49f (a6 integrin) indicated that these cells express
low levels of Sca-1 [4,5]. Instead, CD24
high luminal progenitor
cells were shown to differentiate into Sca-1
+ estrogen receptor (ER)
expressing cells and Sca-1
2/ER
2 cells [6].
When Sca-1 or other Ly6 family members are upregulated on
tumor cells they are commonly associated with an aggressive
phenotype [7]. Sca-1
+ cells are expanded in mammary tumors
induced by Wnt/b-catenin pathway [8,9]. Despite its association
with stem/progenitor cells, little is known about the biological
function of Sca-1. To address this question in the context of
mammary tumor development, we used a cell line derived from
primary tumors of MMTV-Wnt1 transgenic mice, which retained
high expression of Sca-1 and could be transplanted into the
cleared fat pad of syngenic mice. We found that Sca-1 promotes
cell migration and decreases cell adhesion in vitro and regulates
tumorigenicity upon transplantation. Furthermore, Sca-1 regulates
gene expression in multiple pathways involved in tumor
progression. This study demonstrates that modulating Sca-1
expression has profound effects on cellular function and tumor
development.
Results
Sca-1 promotes cell migration
Sca-1 is localized to lipid rafts [2] similar to urokinase
plasminogen activator receptor (UPAR), another well-character-
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27841ized Ly6 family member. UPAR regulates adhesion, migration
and angiogenesis in breast cancer [10]. Therefore, we asked
whether Sca-1 regulates cell migration using a mammary tumor
cell line (Wnt1-YL), derived from primary MMTV-Wnt1 tumors.
Previous studies [4,8] revealed high levels of Sca-1 expression in
MMTV-Wnt1 induced hyperplasia and tumors, and we were able
to develop several cell lines from these tumors. The Wnt1-YL cells
uniformly express high levels of Sca-1 as detected by flow
cytometry (Figure 1A). We then knocked down Sca-1 surface
expression using shRNA lentiviral technology. A shift in mean
fluorescence intensity revealed Sca-1 surface expression was
reduced ,30-fold in the Wnt1-YL-shSca1 (shSca-1) as compared
to control cells transduced with an shRNA targeting luciferase
(shLuc) (Figure 1A). This reduction in Sca-1 expression did not
alter cell growth as assessed by a growth curve over the period of 4
days (Figure 1B). When cell migration was assessed using a wound
healing scratch monolayer assay, shSca-1 cells exhibited a
significantly slower cell migration at 12–24 hours, (Figure 1C
and D). A rescue experiment was next performed by re-
introduction of a Sca-1 expression construct containing an altered
shRNA-binding site, to rule out off-target effects of the Sca-1
shRNA. Re-expression of Sca-1 reversed the migration phenotype,
demonstrating the specificity of the shRNA knockdown (Figure 1C
and D). This was also demonstrated independently by microarray
analysis in which Ly6a, but not other Ly6 family members, was
selectively knocked down by these shRNAs (Table S1). An early
lag phase between 0–12 hours was observed in these rescue
experiments where there is a significant difference between the
Figure 1. Repression of Sca-1 delays cell migration. Flow cytometry analysis of Sca-1 surface expression, representative histograms (A). Growth
curve of shLuc (blue), shSca-1 (red) and shSca-1+Sca-1 (black) cells (B). Images of scratch monolayer migration assay at times 0, 12, and 24 hours (C–
K), representative images of 3 experiments performed in triplicate. shLuc (C–E), shSca-1 (F–G), and shSca-1+Sca-1 (I–K), scale bars=200 mm. Cell
migration graph (L). shLuc (blue), shSca-1 (red), shSca-1+Sca-1 (black), * represents statistical significance compared to shLuc control, (*=p,.05,
***=p,.001).
doi:10.1371/journal.pone.0027841.g001
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this delay was overcome by 18 hours. Notably, the cells appeared
to migrate collectively as a sheet of cells rather than as single cells.
Sca-1 regulates cell adhesion
We hypothesized that the delay in migration in the shSca-1 cells
was attributed to alterations in cell adhesion. In order to determine
if Sca-1 regulates cell adhesion, we evaluated the adhesion of the
Wnt1-YL cells to a panel of extracellular matrix (ECM) proteins
(collagen I, collagen IV, fibronectin, laminin, and vitronectin).
shSca-1 cells showed increased adhesion to fibronectin, collagen I,
collagen IV, and laminin compared to control cells (Figure 2A). In
rescue experiments, adhesion of shSca-1+Sca-1 cells to collagen I,
collagen IV, and fibronectin returned to levels similar to the shLuc
control cells (Figure 2A). The increase in adhesion to laminin was
enhanced in shSca-1+Sca-1 cells (Figure 2A). Additionally, each
group exhibited relatively weak adhesion to vitronectin, however,
the shSca-1+Scal-1 cells showed reduced adhesion compared to
control cells (Figure 2A). These results suggest that delayed
migration exhibited by shSca-1 cells may be due to increased cell
matrix interactions. To investigate the possible cause for these
altered adhesive properties, we evaluated the surface expression of
integrins (receptors for ECM proteins) by flow cytometry. We
analyzed a panel of integrins (a2, a3, a5, a6, aV, b1, b3, and b4)
expressed in normal mammary epithelial cells. a2, a5, a6, aV and
b1 were all expressed (Figure 2B–F); however, only a5-integrin
showed a difference in expression level between the shSca-1 and
control cells. a5-integrin expression increased 1.7 fold in shSca-1
cells (Figure 2C). Notably, a6 and b1, which bind laminin as a
heterodimer were expressed at high levels as compared to their
respective isotype controls (Figure 2D, F). Interestingly, these
receptors have also been used to isolate cancer stem cells in p53
2/
2 mammary adenocarcinomas [11]. These data do not rule out
the possibility that integrin activity rather than expression may be
altered by Sca-1. Alternatively, integrins that were not evaluated
may be aberrantly expressed accounting for the differences in cell
adhesion.
Repression of Sca-1 increases tumor propagation ability
and accelerates tumor growth
We next determined if the alterations in migration and adhesion
in Sca-1-deficient cells would influence tumor propagation and
growth in vivo. To determine if the repression of Sca-1 effects
tumor outgrowth, shSca-1 or shLuc cells were transplanted into
the cleared mammary fat pad of 3–4 week old syngenic recipient
mice, at concentrations ranging from 500–10,000 cells. Limiting
dilution transplantation revealed that shSca-1 cells display a 9-fold
increase in tumor propagating potential (1/654) as compared to
shLuc control cells (1/5963; p..001) (Table 1, [12]). A
significantly greater number of shSca-1 tumors were observed at
lower cell concentrations 2000-500 cells (Table 1).
We subsequently studied tumor latency with injections of
10,000 cells, since both knockdown and control cell lines efficiently
Figure 2. Sca-1 repression leads to increased adhesion to
collagen I, collagen IV and fibronectin. Cell adhesion of 100,000
cells/well coated with fibronectin, vitronectin, laminin, collagen I or
collagen IV comparing shLuc (open bars), shSca-1 (grey bars) and shSca-
1+Sca-1 (black bars). (A). Relative adhesion was normalized to a BSA
control, (* p,.05, ** p,.01, *** p,.001), mean6SEM of three
experiments performed in triplicate. Flow cytometry analysis of integrin
expression a2, a5, a6, aV, b1 (B–F, respectively) representative
histograms.
doi:10.1371/journal.pone.0027841.g002
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a median latency of 2 weeks as compared to 5 weeks for shLuc-
derived tumors (Figure 3A). To determine if the accelerated tumor
development was due to increases in proliferation in the shSca-1
cells or increased cell death in the shLuc control cells, tumor
sections were stained for BrdU and a TUNEL assay, respectively.
This was investigated in both early histological lesions and in
palpable tumors. When mammary fat pads were harvested 2
weeks following transplantation, and early lesions analyzed, 10%
of the shLuc tumor cells were BrdU-positive in comparison to
shSca-1 tumor cells in which 20% were BrdU-positive (Figure 3B–
C, F). However, in established tumors this two-fold difference in
proliferation was not observed, and approximately 20% of the cells
were BrdU-positive cells in both groups (Figure 3D–F). Neither
early lesions nor established tumors showed differences in cell
death (Figure S1), suggesting that the difference in latency was
attributed to a transient increase in proliferation in the early
lesions. These data are consistent with the limiting dilution
transplantation results and suggest that knockdown of Sca-1
influences tumor initiation in this model, but appeared to have
little effect in established tumors.
To determine the histological characteristics of these tumors, we
performed immunostaining for mammary epithelial markers (K5,
K8, pan-Keratin). Interestingly, hemotoxylin and eosin staining
showed a mesenchymal (spindle-shaped) morphology distinctly
different from the transgenic MMTV-Wnt1 tumors from which
the cell line was derived. The tumors were positive for basal
marker K5 (Figure 4), while only a small percentage of the cells
were positive for luminal keratin marker K8, further suggesting a
divergence from the parental MMTV-Wnt1 tumors, which
expressed both basal and luminal keratins [8].
Identification of differentially expressed genes
To determine the potential mechanisms by which Sca-1
regulates cell migration, adhesion, and tumor development, we
performed an Affymetrix mouse genome 430A 2.0 array on cDNA
comparing shLuc and shSca-1 from cells grown in vitro. The array
identified 448 unique genes (574 Affymetrix probe sets) with
p,0.01 and fold change .1.5 (Table S1). One hundred and
twenty six genes were upregulated, and 322 genes were
downregulated (Figure 5A). Importantly, Sca-1 was the only Ly6
family member on the chip that was significantly downregulated.
Differences in gene expression of several genes were verified by
qRT-PCR analysis (Figure S2). Repression of Sca-1 lead to the
upregulation of several inflammatory chemokines: chemokine (c-c
motif) ligand 2 (Ccl2), Ccl7, chemokine (c-c motif) ligand 5 (Cxcl5).
Table 1. Repression of Sca-1 increases tumor outgrowth
potential and tumor propagating cell frequency.
Tumor Take Rate
No. Cells Injected shLuc (%) shSca-1 (%) p-value
10,000 9/10 (90) 11/11 (100) ns
5,000 5/12 (42) 9/9 (100) p,.01
2,000 4/10 (40) 13/14 (93) p,.01
1,000 1/10 (10) 6/7 (86) p,.01
500 1/11 (9) 7/13 (54) p,.01
Tumor Propagating
Cell Frequency
1/5963 cells 1/654 cells
doi:10.1371/journal.pone.0027841.t001
Figure 3. Repression of Sca-1 accelerates tumor growth by a
transient increase in proliferation. Tumor latency plot comparing
shLuc (blue line) and shSca-1 (red line) (A). BrdU staining of early lesions
(B,C) and established tumors (D,E). Bar graph of BrdU staining of shLuc
(open bars) and shSca-1 (grey bars) in early lesions and tumors (F)
(** p,.01).
doi:10.1371/journal.pone.0027841.g003
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involved in proliferation, cell movement, cell-cell signaling and cell
organization (Figure 5B).
Discussion
Sca-1 is widely accepted as a stem/progenitor cell marker in
normal mouse tissues [3,13–15]. However, Sca-1
eGFP/eGFP mice
did not exhibit a reproducible phenotype on mammary gland
development in our laboratory (unpublished data). Previous
studies have shown that Sca-1 positive cells are expanded in
Wnt/b-catenin induced mammary tumors [8,9]. Additionally, a
Ly6 family member, Ly-6D is upregulated in a variety of murine
tumors and triple-negative breast cancers [16]. Despite these
associations there is limited knowledge of functional role of Sca-1.
Our findings indicate that Sca-1 plays an important role in
mammary tumorigenesis as revealed using a novel cell line derived
from MMTV-Wnt-1 mouse mammary tumors. First, Sca-1
promotes cell migration and affects cell adhesion to several
ECM substrates in vitro. Second, Sca-1 regulates the frequency of
tumor propagating cells and tumor cell proliferation in early
lesions. These studies point to epithelial-ECM interactions as
mediators of Sca-1 function; however, direct effects on down-
Figure 4. Wnt1-YL tumors express basal epithelial marker K5.
Immunohistochemical staining of early tumor lesions of shLuc- and
shSca-1-derived tumors. Hemotoxylin and eosin staining (A–B), Keratin
5 (C–D), Keratin 8 (E–F), pan-Keratin (G–H).
doi:10.1371/journal.pone.0027841.g004
Figure 5. Gene expression analysis of shLuc and shSca-1 cells.
Heat map of differentially expressed genes between shLuc and shSca-1
cells (A) up-regulated genes (yellow) and down-regulated (blue). Table
of pathways enriched in Sca-1 deficient cells (B).
doi:10.1371/journal.pone.0027841.g005
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yet been determined.
There are several plausible explanations for our observations.
First, Sca-1 may directly (or indirectly) interact with integrins
modulating their ability to heterodimerize and bind ECM
proteins, and/or modulating the strength of integrin-ECM
interactions. The increased expression of a5-integrin in shSca-1
cells likely accounts for the increased adhesion to fibronectin via
the a5b1 heterodimer. a5-integrin has been implicated as a
suppressor of metastasis and a6-integrin promotes metastasis in
breast cancer cell lines [17]. Since both of these integrins are
expressed at similar levels in the Wnt1-YL cells, further
investigation is required to fully define the relationship between
Sca-1 and the role of integrins in this system. Next, Sca-1 may
interact with non-integrin receptors such as growth factor
receptors that cooperate with integrin signaling [18–20]. Alterna-
tively, Sca-1 may alter interactions with cell surface receptors that
act independently of integrin signaling. Additionally, Sca-1 may
regulate the activation of MMPs leading to the release/activation
of growth factors stimulating proliferation of tumor cells as
observed in skeletal muscle cell regeneration [21].
The Wnt1-YL cells exhibited collective cell migration as a sheet
in a scratch monolayer assay. In transwell migration assays,
evaluating single cell migration across a porous membrane we did
not show statistically significant differences in migration (data not
shown). Furthermore, when the cells were seeded in matrigel
(laminin-rich matrix) for a 3D morphogenesis/invasion assay the
cells did not exhibit differences in terms of acini/colony formation
frequency, size, morphology or invasive properties (data not
shown). These observations suggest that Sca-1 is responsible for
subtle changes in cell-cell and cell-ECM interactions in this cell
line. Deciphering these subtleties in the context of cell migration
and invasion may require further investigation of this cell line on
matrices of single ECM substrates.
Interestingly, repression of Sca-1 alters chemokine expression,
influencing the recruitment of inflammatory infiltrates. Since
immune cells influence many processes including angiogenesis, cell
invasion, matrix remodeling, interactions between tumor cells and
the immune system have become of increasing interest in the past
decade. Immune cells in both the innate and adaptive immune
systems have proved to be important in tumor development and
metastasis [22–25]. Chemokine secretion from shSca-1 cells may
recruit immune cells with pro-tumor activities accounting for the
accelerated tumor growth. Furthermore, Sca-1 not only regulates
chemokine expression, but Wnt1-YL cells grown in culture show
differential secretion of both cytokines and chemokines (data not
shown). Also, insulin degrading enzyme (Ide-1), a protein that
physically interacts with Sca-1 to regulate differentiation skeletal
muscle cells [2], was down regulated in shSca-1 cells. Ide-1
catalyzes the degradation of mitogenic peptides attenuating
proliferative signals. Reduction in this activity may also account
for proliferative response seen the shSca-1 tumor development.
Additionally, Fgf20, a Wnt/b-catenin target gene, was up
regulated in response to Sca-1 repression. Cooperation between
the Wnt/b-catenin and FGF signaling pathways has been reported
in human cancers and our laboratory has previously shown a
strong association leading to rapid proliferation upon simultaneous
activation of these pathways [20]. Thus, Sca-1 potentially regulates
multiple aspects of tumor development. The impact of these
changes in mRNA expression needs to be determined with regard
to protein expression and activity to better understand the role of
Sca-1 in tumorigenesis.
Recently, Upadhyay and colleagues showed that Sca-1
inhibited TGF-b signaling by disrupting the heterodimerization
of the TGF-b receptors and repressing expression of Gfd10, a
TGF-b ligand, in a mammary adenocarcinoma cell line induced
by medroxyprogestrone (MP) and 7,12-dimethylbenz(a)anthra-
cene (DMBA) [26]. Their tumor outgrowth data indicate that
repression of Sca-1 reduces tumorigenicity or outgrowth
potential as observed in normal mammary epithelial cells.
Similarly, another report shows delayed tumor development in
MP/DMBA induced tumors in Sca-1 knock-out mice [27]. In
this case, the delay in tumor development was attributed to the
upregulation and activation of PPARc. In contrast, our data
indicate that Sca-1 may restrict cell growth. There are several
explanations for these discrepancies. First, the tumors were
developed under different conditions likely driven by different
signaling pathways, which have been shown to yield very
different tumor histopathologies [8]. Second, the relative level of
Sca-1 on the cell surface is likely to govern how Sca-1 regulates
signaling activities [1]. This may also account for the lack of
overlapped genes in the microarrays when comparing the data of
Upadhyay et. al. and our data set. Yuan et. al. only shared 15
g e n e si nc o m m o nw i t ho u rd a t as e tw i t hap ,0.01 and a fold
change .1.5 (Table S2). These genes were all upregulated, but
did not reveal an enrichment of a common functional pathway.
Since the tumor cell models employed in the two studies were
developed using different methods, it is likely that they express
Sca-1 at different levels. Furthermore, it is unlikely that the
efficiency of Sca-1 repression is the same as different shRNA
constructs were used. Cell context no doubt plays an important
role in influencing the effects of Sca-1 in tumors that may have
been derived from very different cell lineages. For instance,
CD24
high/Sca1
2 luminal mammary epithelial cells (MECs) do
not express ER and PR and have increased in vitro progenitor
activity in contrast to CD24
high/Sca-1
+ luminal MECs that are
ER and PR positive with reduced in vitro progenitor activity [6].
Nevertheless, these studies highlight that Sca-1 likely regulates
multiple cellular processes.
In conclusion, we provide evidence that Sca-1 regulates multiple
cellular functions in mammary tumor cells. Our data highlight the
importance of studying Sca-1 in the context of tumor develop-
ment. To definitively differentiate the roles that Sca-1 plays in
tumor initiation and tumor progression it will be necessary to use a
conditional system in which Sca-1 can be knocked at various stages
of tumor development. Additionally, it may be necessary to
evaluate the role of Sca-1 in tumor subpopulations in models in
which tumor-initiating cells are present. Further investigations
along these lines will lead to a better understand of GPI anchored
protein functions in tumors.
Materials and Methods
Ethics Statement
Mice were maintained in accordance with the National
Institutes of Health Guide for the Care and Use of Experimental
Animals with approval from the Baylor College of Medicine
Institutional Animal Care and Use Committee (Animal Protocol:
AN-504).
Cell Line
The Wnt1-YL cell line was derived from an invasive carcinoma
(ZD2508) of an MMTV-Wnt1 FVB/n mouse. The cells were
grown in DMEM/F12 (Invitrogen) at ph 7.6, with 2% adult
bovine serum (Gemini Bio-Products), antibiotic/antimycotic (In-
vitrogen), 5 mg/ml gentimycin (Sigma), 10 mg/ml insulin (invitro-
gen) and 5 ng/mL EGF (Invitrogen).
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pLKO lentiviral vectors (Open Biosystems) with shRNA
targeting Sca-1 were used to repress expression of Sca-1. The
LeGO-Sca-1-iG2 was constructed by PCR amplifying Sca-1
cDNA from the pSport6-Sca-1 plasmid (Open Biosystems) using
the follow primers: 59-GCCGGGATCCCTGAGAGGAAGTTT-
TATCTGT-39 and 59-GCCGGAATTCTCAGAGCAAGGT-
CTGCAG-39. The PCR product was digested BamHI and EcoRI
cloned into the LeGO-iG2 expression vector.
Lentiviral Transductions
293T-packaging cells were transiently transfected with pLKO-
shRNA vectors (Open Biosystems), Gag-Pol and VSV-G plasmids
using FuGENE 6 (Roche) according to the manufacturer’s
guidelines. Forty-eight hrs after transfection, virus-containing
medium was collected from transfected 293T cells, filtered through
a 0.45-mm syringe filter, and applied to Wnt1-2508 cells. The cells
were spun at 300 g in a swinging platform rotor for 30 min. After
24 hrs, the lentiviral supernatant was removed from Wnt1-2508
cells and replaced with fresh medium. Forty-eight hrs later, cells
were trypsinized and split at a low density with the addition of
4 mg/ml puromycin (Sigma) to select for transduced cells.
Transplants
Clearance of the mammary fat pad and MEC transplantation
procedures were performed as previously described [28]. Cells
were trypsinized with 0.25% Trypsin-EDTA (Invitrogen) and
counted using a Vi-CELL XR Cell Viability Analyzer (Beckman
Coulter). The designated number of cells were washed and
resuspended in Hank’s balanced salt solution (Invitrogen). The
cells were injected into the cleared inguinal fat pad of 3–4 week old
FVB/n mice (Harlan). Tumors were allowed to develop for up to
16 weeks.
Growth Curve
Cells were plated at 50,000 cells/well in 6-well plates and
replenished with fresh medium every 48 hrs. Cells were trypsin-
ized and counted every 24 hrs 4 days using a Vi-CELL XR Cell
Viability Analyzer (Beckman Coulter).
Adhesion Assay
10
5 cells were seeded onto CytoMatrix
TM Cell Adhesion Strips
coated with BSA, Collagen Type I and IV, Fibronectin, Laminin,
Vitronectin (Millipore) according to the manufacturer’s guidelines.
The cells were allowed to adhere for 1 hr at 37uC, non-adherent
cells were washed off with PBS, and adherent cells were stained
with 0.2% crystal violet. The relative attachment was determined
by absorbance at 560 nm on a microplate reader and all samples
were normalized to BSA coated wells. Statistical analysis was
performed by one-way ANOVA followed by Tukey’s multiple
comparisons test.
Migration Assay
Cells were grown to confluence in 6-well plates. A p1000 pipet
tip was used to make a scratch down the center of each well.
Pictures were taken on an inverted microscope (Zeiss) every 6 hrs
for 24 hrs to evaluate migration across the scratch. Following the
scratch, the cells were wash and refreshed with complete media.
Axiovision software (Zeiss) was used to measure the distance across
each scratch. For each experiment, 3 fields along the scratch of
each well were analyzed in triplicate for each sample. A two-way
ANOVA followed by Bonferroni tests was used to compare the
mean at each time point.
mRNA Real Time-PCR
cDNA templates were generated using a SuperScript II as
previously described. Quantitative PCRs were run using SYBR
Green reagent (Applied Biosystems) on a StepOnePlus thermo-
cycler (Applied Biosystems), normalized to b-actin, and fold
changes were calculated using the comparative CT (DDCT)
method using StepOne software v2.0.1 (Applied Biosystems).
Primer sequences for Sca-1, Ccl2, Ccl7, Cxcl5, Mmp-9, and
S100a8 were obtained from (Roche Applied Science).
Flow Cytometry
Cells were trypsinized, trypsin was neutralized with culture
medium containing ABS and centrifuged at 4506 g for 5 min,
and the cell pellet was resuspended in HBSS containing 2%
ABS (HBSS+). Cells were counted and separated for labeling
with antibodies. The cells were incubated primary antibodies for
20 minutes on ice, washed twice with HBSS+ and resuspended
with HBSS+ containing Sytox Blue or Sytox Red (Invitrogen) to
exclude dead cells. The cell suspensions were filtered using
40 mm filter (BD Falcon) and analyzed on a LSRII Fortessa
(Becton Dickinson). The following primary antibodies were
used: PE-conjugated (PE) rat anti-mouse Sca-1 (1:100; BD
Pharmingen), APC hamster anti-mouse/rat CD 29 (1:100;
BioLegend), FITC hamster anti-mouseCD49b (1:100;
eBioscience), PE mouse anti-human CD49c (1:100; BD
Pharmingen), PE rat anti-mouse CD49e (1:100; BD Pharmin-
gen), FITC rat ant-human CD49f (1:100; BD Pharmingen), PE
rat anti-mouse CD51 (1:100; BD Pharmingen), Alexa Fluor 647
hamster anti-mouse/rat CD61 (1:100; BioLegend), PE rat anti-
human CD104 (1:100; BD Pharmingen) and the corresponding
isotype controls.
Immunohistochemistry and Immunofluorescence
Mice were injected with 3 mg/mL BrdU (0.01 mL/g body
weight) two hrs prior to sacrifice. Tumors were harvested and fixed
in 4% paraformaldehyde for two hrs on ice. Tissues were
embedded in paraffin blocks and 6–8 mm sections were cut for
immunostaining. Sections were boiled in sodium citrate antigen
retrieval buffer for twenty minutes. Sections were blocked with a
5% BSA, 0.05% Tween-20 in PBS for immunohistochemistry and
in 10% goat serum in PBS for immunofluorescence. Primary
antibodies were incubated at 4uC overnight. BrdU (1:10; BD), K5
(1:10,000; Covance), K8 (1:5000; Univ. of Iowa), pan-Keratin
(1:5000; Sigma).
Microarray
Total RNA was isolated from cells using TRIzol Reagent
(Invitrogen) and then cDNA was made from total RNA with
SuperScript II (Invitrogen) using random primers. cDNA was
treated with RNase H (Invitrogen) to remove RNA. Microarray
analysis was done with Affymetrix MG 430 2.0 chip. Statistical
analysis was done with dChip software package (www.dChip.org),
using PM-MM model and invariant set normalization. Differen-
tially expressed genes were identified using two-sided t-test and
fold change on log-transformed data. Java TreeView represented
expression values as color maps [29]. Microarray data have been
deposited into the Gene Expression Omnibus database
(GSE30684) and followed MIAME requirements.
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Figure S1 Repression of Sca-1 did not alter cell death.
TUNEL staining of tumor sections (A–E). Positive control,
DNaseI-treated shLuc tumor section (A). shLuc and shSca-1 early
lesions (B, C) and tumors (D, E).
(TIF)
Figure S2 qRT-PCR analysis of selected genes in shLuc
and shSca-1 cells. Relative mRNA expression of Sca-1, Mmp-
9, S100a8, Cxcl5, Ccl2, and Ccl7 (A–F, respectively).
(TIF)
Table S1 Differentially expressed genes in shSca-1
tumor cells. Listed are statistically significant genes with
p,0.01 and a fold change .1.5 in shSca-1 cells compared to
shLuc control cells.
(XLS)
Table S2 Upregulated genes associated with Sca-1 loss
in tumors. Listed are the statistically significant genes upregu-
lated with p,0.01 and a fold change .1.5 in both shSca-1 cells
and MP/DMBA tumors in Sca-1 knockout mice.
(XLS)
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